HIGHLIGHTS
- Who: Dandan Liu from the The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi`an Jiaotong University, Xi`an, Shaanxi, China have published the research: Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?, in the Journal: (JOURNAL)
SUMMARY
Methods Patients with T2N0-1M0 HR-positive/HER2-negative BC who underwent BCS between 2010 and 2017 were selected from the SEER database. In the T2N0-1M0 population and T2N1M0 subgroup, AC patients before PSM had better OS and BCSS than NAC . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.